24 results about "Angiogenesis inhibitor" patented technology

The application relates to the technical field of biomedical materials, in particular to a wound paste for preventing skin scar formation and a preparation method thereof. The wound paste for preventing skin scar formation comprises an integrated composite film comprising an adhesion layer and a functional layer; the adhesion layer comprises first silk fibroin and metal ions; the metal ions have at least one of the effects of antibiosis, anti-inflammation and pro-angiogenesis; the functional layer comprises composite fibers with a core-shell structure; the core of the composite fiber comprises second silk fibroin and an angiogenesis inhibitor, and the shell comprises third silk fibroin. The wound paste is good in biocompatibility, convenient to apply, gradually releases effective components, adapts to the healing process of a wound, and is more scientific and effective in preventing scar formation.

Systems and methods for destroying or inhibiting cancer cells and other rapidly-dividing cells including an alternating polarity (AP) magnetic field generator and one or more AP electromagnetic coil adapted to be coupled to at least a portion of a patient's body, and a controller to control the AP magnetic field generator and at least one AP electromagnetic coil and cause the field generator and coil to apply AP magnetic field having a frequency of 0.5-500 KHz and a field strength of 0.5-5 mT to the at least a portion of the patient's body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer therapy such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, an angiogenesis inhibitor drug, or tumor treatment field therapy.

This disclosure provides antibodies that bind to human adhesion G protein-coupled receptor B1 (BAI1) protein, compositions comprising said antibodies, and their use in detection, diagnostic, and therapeutic methods. Sequences of complementarity-determining regions (CDRs) in the variable heavy chain (VH) and variable light chain (VL) sequences, as well as the amino acid sequences of VH and VL, are also provided.

The invention relates to an application of 2-methyl-4 (3H)-quinazolinone in preparation of an anti-angiogenesis medicine. The invention discloses the application of the 2-methyl-4 (3H)-quinazolinone compound as an angiogenesis inhibitor in anti-angiogenesis drugs for the first time, and the 2-methyl-4 (3H)-quinazolinone compound has a remarkable inhibition effect on internode blood vessels and dorsal longitudinal anastomosis angiogenesis of a Tg (flk: mCherry) fluorescent transgenic zebrafish strain. Meanwhile, the growth of the zebrafish embryos of the strain is not obviously influenced, and the toxicity is extremely low. The compound not only can be extracted from streptomyces, but also can be obtained through an artificial synthesis process, has a reliable and stable source, and has a good application prospect in the field of anti-angiogenesis drugs.

A method of treating a solid tumor or subdural hematoma in a subject in need thereof is described. The method includes administering a therapeutically effective amount of biocompatible polymeric microparticles comprising an angiogenesis inhibitor to the solid tumor using targeted endovascular administration.

In combination with conventional therapies (e.g., targeted therapy, chemotherapy, and angiogenesis inhibitors etc.), immunotherapies targeting checkpoint molecules have shown promise in the treatment of solid or liquid tumors. However, apoptotic regulatory T cells (Treg) induced by such therapies often become more suppressive in the tumor microenvironment (TME), through increased generation of adenosine tightly controlled by ectonucleotidases, viz. CD39 and CD73. CD39 / ENTPD1, a novel checkpoint molecule, is highly expressed and activated on the tumor vasculature and infiltrating immune cells, promoting tumor growth. Deletion or blockade of CD39 enhances anti-tumor activity by augmenting anti-tumor immune responses and inhibiting tumor angiogenesis. The present invention is based at least in part on the development of anti-CD39 antibodies which mediate CD39 downregulation on immune cells, such as T-cells with markers of T-cell exhaustion, and the demonstrated utility of these antibodies in blocking tumor growth with minimal side effects in pre-clinical models.

The invention provides application of corydalis saxicola bunting in preparation of anti-angiogenesis drugs. The invention provides application of a corydalis saxicola bunting plant, a traditional Chinese medicinal material of the corydalis saxicola bunting plant or a corydalis saxicola bunting plant extract in preparation of anti-angiogenesis drugs. According to the present invention, the in vivo pharmacodynamic experiment performed by using the zebra fish angiogenesis model for the first time proves that the corydalis saxicola bunting extract can significantly inhibit the angiogenesis of zebra fish, such that the corydalis saxicola bunting extract has the anti-angiogenesis activity, and can be used as the angiogenesis inhibitor, the compound can be applied to treatment of neovascularization-dependent and neovascularization-related diseases such as tumors, arthritis, skin and ophthalmic diseases, atherosclerosis, vascular dementia, endometriosis and the like.

The present disclosure relates to methods of treating cancer, such as lung cancer (e.g., non-small cell lung cancer) by administering a dry powder to the respiratory tract of a subject in need thereof (e.g., by oral inhalation), the dry powder comprising respirable dry particles that comprise an angiogenesis inhibitor (e.g., itraconazole), and optionally a stabilizer (e.g., polysorbate 80) and / or one or more excipients (e.g., leucine and a sodium salt, such as sodium sulfate).

The disclosure provides methods and devices for the treating or preventing a benign uterine disorder in a female mammalian subject. The methods comprise administering a non-steroidal angiogenesis inhibitor. Such methods and devices are particularly useful for treating women suffering from adenomyosis and related symptoms.

The present invention relates to mouse antibodies that bind to angiopoietin-2 (Ang2), humanized anti-Ang2 antibodies derived therefrom, and the use thereof. The anti-Ang2 antibodies have a dual function of activating the Tie2 receptor together with neutralizing Ang2. The anti-Ang2 antibodies show the property of normalizing abnormal and pathological blood vessels, and thus exhibits therapeutic efficacy against various diseases and disorders associated with abnormal blood vessels. The present invention further provides an angiogenesis inhibitor and a composition for treatment of diseases associated with abnormal Ang2 expression and Tie2 dysregulation, which comprise the antibody as an active ingredient, and a composition for diagnosing diseases associated with Ang2 inhibition and Tie2 activation, which comprises the antibody.

The present invention relates to a cancer therapeutic composition for inhibiting angiogenesis, and a method for preparing the same. The angiogenesis inhibitor according to the present invention is a cancer therapeutic composition containing a fusion protein including a vascular endothelial growth factor binding domain of vascular endothelial growth factor receptor 1 (VEGFR1) and a b1 domain of neuropilin 1 (NRP1). The novel fusion protein is an angiogenesis inhibitor for blocking the binding of VEGF to its receptor on a cell membrane, and has an effect of inhibiting the proliferation of cancer cells as well as the growth and metastasis of cancer. In addition, the fusion protein can be used as an anticancer agent, and exhibits an effective anticancer effect at a lower dose than conventional angiogenesis inhibitors.

The invention discloses application of anlotinib combined chemotherapy in preparation of a medicine for treating esophagus cancer in a new adjuvant therapy mode, experimental verification shows that the anlotinib combined chemotherapy has high clinical and pathological remission rate in the new adjuvant therapy of esophagus cancer patients, and meanwhile compared with chemotherapy combined radiotherapy, the operation difficulty can be reduced, the operation time can be shortened, and the esophagus cancer treatment efficiency can be improved. In addition, the occurrence rate of complications in the perioperative period is not increased, and assistance is provided for accelerating postoperative rehabilitation (ERAS). Therefore, in the neoadjuvant therapy of the esophageal cancer patient, the micromolecular multi-target angiogenesis inhibitor combined chemotherapy can improve the feasibility of the neoadjuvant therapy of the esophageal cancer and reduce the surgical technical threshold after the neoadjuvant therapy, so that the technology can be more widely popularized and applied; according to the application, the micromolecular multi-target angiogenesis inhibitor is used as a new selection mode for new adjuvant therapy of esophageal cancer patients.

Described herein are compositions for modulating transgene expression of one or more therapeutic agents. In some aspects, an engineered polynucleotide comprises one or more expression cassettes, the one or more expression cassettes encoding a first angiogenesis inhibitor and a second angiogenesis inhibitor. Also described herein are methods of using the compositions described herein for modulating transgene expression and for treating diseases or conditions, in particular therapeutic agents for treating ocular diseases or inhibiting neovascularization.

To provide a novel treatment method for benign nervous system tumors, including schwannomas; and to provide a composition for use in the treatment method.SOLUTION: Provided herein are methods for a treating a subject having or at risk of having a benign nervous system tumor. The methods include administering to the subject a therapeutically effective amount of a composition comprising live attenuated Salmonella bacteria, optionally in combination with an immune checkpoint inhibitor and / or angiogenesis inhibitor. Preferably, the attenuated Salmonella is an attenuated strain of S. typhimurium, e.g., Salmonella enterica serovar typhimurium strain VNP20009 with modified lipid A (msbB-) and purine auxotrophic mutation (purI-).SELECTED DRAWING: None

Providing pharmaceutical compositions for the treatment of melanoma. [Solution] A pharmaceutical composition comprising (a) an LXRβ agonist selected from the following compounds 1, 2, 12, and 25, and / or a salt thereof, and (b) an antiproliferative compound selected from immunomodulators, topoisomerase inhibitors, antimetabolites, angiogenesis inhibitors, tyrosine kinase inhibitors, alkylating agents, and mitotic inhibitors. TIFF2026062949000078.tif110166

Provided is a drug for treating and / or preventing cancer. A drug for the treatment and / or prevention of cancer, which comprises an antibody having immunoreactivity with CAPRIN-1 protein or a fragment thereof together or separately in combination with an anthracycline-based drug and a platinum preparation, or an anthracycline-based drug, a platinum preparation and an angiogenesis inhibitor (however, does not comprise a pyrimidine-based drug).

Disclosed herein include methods, compositions, and kits suitable for use in treating cancer. In some embodiments, the method comprises administrating a topoisomerase I inhibitor and onvansertib to a subject with cancer, thereby inhibiting progression of the cancer. The method can further comprise an angiogenesis inhibitor. The method can include sensitizing cancer cells to a topoisomerase I inhibitor, by contacting the cancer cells with a composition comprising onvansertib.

This specification describes compositions for modulating the transgene expression of one or more therapeutic agents. In some embodiments, engineered polynucleotides comprising one or more expression cassettes encoding a first angiogenesis inhibitor and a second angiogenesis inhibitor are described. Similarly, this specification describes methods of using the compositions described herein for modulating transgene expression and for treating diseases or conditions, particularly for treating eye diseases or inhibiting angiogenesis.

The application discloses an anti-vascular composite gene vector and a preparation method and application thereof. The anti-vascular composite gene vector is prepared by coating the cationized tussah silk fibroin which is modified by an angiogenesis inhibitor, endostatin, on the surface of an adenovirus by electrostatic adsorption. The anti-vascular composite gene vector is in the form of spherical nano-particles, can effectively infect umbilical vein endothelial cells and liver cancer cells, express anticancer genes, inhibit the proliferation of vascular endothelial cells and tumor cells, and block the growth and metastasis of tumors. Different anticancer genes are coded in the vector, so that the anti-vascular composite gene vector can play the therapeutic effect of resisting tumors and preventing metastasis for different malignant tumors. Therefore, the anti-vascular composite gene vector can be used for preparing a medicine for treating tumors.

In combination with conventional therapies (e.g., targeted therapy, chemotherapy, and angiogenesis inhibitors, etc.), immunotherapy targeting checkpoint molecules has shown promise in treating solid or liquid tumors. However, the role of non-tumor cells in the intratumoral microenvironment has indicated that the elimination of these cells may be key to generating an effective immune response against the tumor, including tumor infiltration of cytotoxic T cells and other anti-tumor cells of the immune system. The present invention does not focus on attempting to inhibit the ectonucleotidase activity of CD39 as an enzyme that produces adenosine, but rather utilizes CD39 expression to achieve intratumoral cell elimination through CD39-dependent ADCC.

The invention discloses a mesenchymal stem cell loaded with attenuated salmonella, which is prepared by the following steps: loading attenuated salmonella VNP by using a mesenchymal stem cell (MSC) to obtain an MSC-VNP cell; the attenuated salmonella is attenuated salmonella typhimurium VNP20009 and a derivative or gene modified strain thereof, and the strain is an expression plasmid which does not carry or carries an expression therapeutic gene and a tracer protein exogenous gene; the therapeutic gene is a coding gene of a protein which can be expressed in attenuated salmonella and has a therapeutic effect, and comprises a cell apoptosis anti-tumor gene, an angiogenesis inhibitor gene or an immune checkpoint blocker antibody gene, and the foreign gene of the tracer protein is Dsred; the expression plasmid is provided with a promoter lac which is commonly used in attenuated salmonella; and the plasmid contains an anti-plasmid loss element AT. The mesenchymal stem cell can effectively load the attenuated salmonella, can also effectively release the attenuated salmonella, and can be used as a universal cell therapy carrier, so that the therapy cost is saved.

The present invention relates to an antibody fragment specifically binding to vascular endothelial growth factor (VEGF) and, more specifically, to a dimeric antibody fragment comprising a structure in which two antibody fragments are dimerized by a SARAH domain, and expressing high binding affinity and excellent biological activity for VEGF. The antibody of the present invention inhibits VEGF-induced proliferation of human vascular endothelial cells (HUVEC) and blocks VEGFR2-mediated signaling, and thus effectively inhibits angiogenesis.

The present disclosure in some aspects relates generally to anti-angiogenesis compounds, such as deuterated quinoline derivatives, salt thereof, use thereof, and method of preparation thereof. The present disclosure in some aspects relates generally to angiogenesis inhibitors and methods of their use for treating angiogenesis, such as diabetic retinopathy.

The invention relates to the field of medicine, namely to ophthalmology, and can be used in the combined treatment of active retinopathy of prematurity type 1 in zone 1, in children with a gestational age of less than 28 weeks. The technical objective is to develop an effective method for the combined treatment of active retinopathy of prematurity type 1 in zone 1, in children with a gestational age of less than 28 weeks, by performing simultaneous transpupillary laser coagulation of the retina only in the nasal quadrants and introducing an angiogenesis inhibitor into the vitreous cavity. The proposed method solves this problem, involving simultaneous transpupillary laser photocoagulation of avascular zones of the retina in the nasal quadrants only and the injection of an angiogenesis inhibitor into the vitreous cavity. This method prevents the development of tractional retinal detachment, which causes blindness and low vision in children, reactivation of active ROP, and postoperative uveitis, which require additional surgical treatment, in 100% of cases.